A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer

• DOI: 10.1186/s12967-023-04705-3
• Publication Date: 2024-02-21T09:04:00Z
• Authors: Mike Mason; Óscar Lapuente-Sa...; Anni S. Halkola; Wenyu Wang; Raghvendra Mall; Xu Xiao; Jacob Kaufman; Jingxin Fu; Jacob Pfeil; Jineta Banerjee; Verena Chung; Han Chang; Scott D. Chasalow; Hung Ying Lin; Rongrong Chai; Thomas Yu; Francesca Finotello; Tuomas Mirtti; Mikko I. Mäyränpää; Jie Bao; Emmy W. Verschuren; Eiman I. Ahmed; Michele Ceccarelli; Lance D. Miller; Gianni Monaco; Wouter R. L. Hend...; Shimaa Sherif; Lin Yang; Ming Tang; Shengqing Stan Gu; Wubing Zhang; Yi Zhang; Zexian Zeng; Avinash Das Sahu; Yang Liu; Wenxian Yang; Davide Bedognetti; Jing Tang; Federica Eduati; Teemu D. Laajala; William J. Geese; Justin Guinney; Joseph D. Szustak...; Benjamin G. Vincent; David P. Carbone
• Keywords: Immune checkpoint

Predictive biomarkers of immune checkpoint inhibitor (ICI) efficacy are currently lacking for non-small cell lung cancer (NSCLC). Here, we describe the results from Anti-PD-1 Response Prediction DREAM Challenge, a crowdsourced initiative that enabled assessment predictive models by using data two randomized controlled clinical trials (RCTs) ICIs in first-line metastatic NSCLC.